Truist Financial analyst Jailendra Singh maintains $Medpace (MEDP.US)$ with a hold rating, and sets the target price at $347.
According to TipRanks data, the analyst has a success rate of 30.1% and a total average return of -16.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Medpace (MEDP.US)$'s main analysts recently are as follows:
The firm indicated that Medpace anticipates cancellations from the first to the third quarter to persist, potentially affecting book-to-bill ratios from the fourth quarter of 2024 to the second quarter of 2025. This would suggest a return to a book-to-bill ratio of 1.2x may not be feasible until the second half of 2025 at the earliest.
The firm indicates that it may be challenging for Medpace to experience much expansion in its multiple, given the low net new business and a potential dip in revenue growth by 2025. Nevertheless, the company's recent cancellation problems are considered likely to be short-lived, with expectations of a robust acceleration going into 2026.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
储亿银行分析师Jailendra Singh维持$Medpace (MEDP.US)$持有评级，目标价347美元。
根据TipRanks数据显示，该分析师近一年总胜率为30.1%，总平均回报率为-16.2%。
此外，综合报道，$Medpace (MEDP.US)$近期主要分析师观点如下：
该公司表示，medpace预计从2024年第一季度到第三季度的取消情况可能会持续，可能会影响到2024年第四季度到2025年第二季度的订单比例。这将意味着要到最早2025年下半年才有可能恢复到1.2倍的订单比例。
公司指出，鉴于低净新增业务和2025年可能出现营业收入增长的下降，medpace在多个领域经历大幅扩张可能具有挑战性。尽管如此，公司最近的取消问题可能是短暂的，预计会在2026年加速增长。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
